Journal article

Colonisation endpoints in Streptococcus pneumoniae vaccine trials

Kari Auranen, Hanna Rinta-Kokko, David Goldblatt, Hanna Nohynek, Katherine L O'Brien, Catherine Satzke, Birgit Simell, Antti Tanskanen, Helena Kayhty

Vaccine | ELSEVIER SCI LTD | Published : 2013

DOI: 10.1016/j.vaccine.2013.08.061

Grants

Awarded by Bill and Melinda Gates Foundation through the Grand Challenges in Global Health Initiative

Awarded by National Institute for Health Research

Funding Acknowledgements

This study was supported as a part of the research of the PneumoCarr Consortium funded by a grant (37875) from the Bill and Melinda Gates Foundation through the Grand Challenges in Global Health Initiative.

Citation metrics

22Web of Science
27Scopus

Keywords

Ve(t)
Combined Vaccine Efficacy Against Acquisition and Duration of Colonisation
Vaccine (sero)type(s)
Odds Ratio
Or
Non-Vaccine (sero)type(s)
Pneumococcal Conjugate Vaccine
Vt
Medicine, Research & Experimental
Nvt
Immunology
Immunogenicity
Infancy
Science & Technology
Disease
Ve(col)
Vaccine Efficacy Against Acquisition of Colonisation
Nasopharyngeal Carriage
Nasopharyngeal Colonisation
Outcome Assessment, Health Care
Cross-Sectional Studies
Carrier State
Trial Endpoint
Outcome Assessment (health Care)
Ve(acq)
Nasopharynx
Vaccine Efficacy
Pcv
Prevalence
Humans
Streptococcus Pneumoniae
Pneumococcal Vaccines
Efficacy
Vaccine Efficacy Against Colonisation
Pneumococcal Infections
Pneumococcal Carriage Group (pneumocarr)
Pneumococcus
Impact
Immunization
Life Sciences & Biomedicine
Research & Experimental Medicine